semagacestat for alzheimer's disease
DESCRIPTION
A review of a drug, Semagacestat, for the treatment of Alzheimer's Disease, that did not get approved by the FDA due increased side effects.TRANSCRIPT
![Page 1: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/1.jpg)
Termination of a Phase 3 Trial of Semagacestat for the Treatment of Alzheimer's Disease
Rod BugawanNovember 14, 2013
Lipscomb University College of Pharmacy
![Page 2: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/2.jpg)
Learning Objectives
• Describe Alzheimer’s Disease (AD) and recognize the risk factors
• Describe the pathophysiology of AD• Recall the currently approved drug treatments• Describe semagacestat’s mechanism of action• Explain semagacestat’s role in therapy
![Page 3: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/3.jpg)
What is Alzheimer’s Disease
• Alios Alzheimer – 1906• Not a normal part of aging• Irreversible, progressive brain disease:– Slowly destroys memory and thinking skills– Disorientation and ability to reason– Death
• Risk factors: old age, family history, genetics (APOE-e4)
http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics
![Page 4: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/4.jpg)
Epidemiology and Costs
• More than 5 million American are living with Alzheimer’s Disease (AD). 6th leading cause of death in the United States (US)
• 1 out of every 3 Seniors in the US die from AD or other dementia
• $203 Billion for 2013, $1.2 trillion by 2050• In 2012, 15.4 million caregivers provided more
than 17.5 billion hours of unpaid care valued at $216 billion
http://www.alz.org/alzheimers_disease_facts_and_figures.asp
![Page 5: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/5.jpg)
http://www.alz.org/alzheimers_disease_facts_and_figures.asp
Change in number of deaths (2000-2010)
![Page 6: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/6.jpg)
Learning Objectives
• Describe Alzheimer’s Disease (AD) and recognize the risk factors
• Describe the pathophysiology of AD• Recall the currently approved drug treatments• Describe semagacestat’s mechanism of action• Explain semagacestat’s role in therapy
![Page 7: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/7.jpg)
Pathophysiology
https://neurowiki2012.wikispaces.com/Down+Syndrome
• Amyloid-beta plaques• Neurofibrillary tangles• Neuronal degradation
![Page 8: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/8.jpg)
Pathophysiology
• Schematic depiction of the process of amyloid-beta (AB) protein plaque formation. (National Institute on Aging)
https://neurowiki2012.wikispaces.com/Down+Syndrome
Beta and Gamma Secretase
Aβ protein plaques in cortex and hippocampus
APPAmyloid Precursor Protein
![Page 9: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/9.jpg)
Learning Objectives
• Describe Alzheimer’s Disease (AD) and recognize the risk factors
• Describe the pathophysiology of AD• Recall the currently approved drug
treatments• Describe semagacestat’s mechanism of action• Explain semagacestat’s role in therapy
![Page 10: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/10.jpg)
Current FDA approved drugs• Cholinesterase inhibitors for mild to moderate AD– Work by stopping the breakdown of the acetylcholine, a
neurotansmitter needed for communication– Donepazil, galantamine, rivastigmine, tacrine
• N-methyl-D-aspartate (NMDA) receptor antagonists for moderate to severe AD– Brains most prominent excitatory neurotransmitter– Works by regulating excess glutamate caused by AD, slowing
down neuronal damage– Memantine
http://www.alz.org/alzheimers_disease_standard_prescriptions.asp
![Page 11: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/11.jpg)
Learning Objectives
• Describe Alzheimer’s Disease (AD) and recognize the risk factors
• Describe the pathophysiology of AD• Recall the currently approved drug treatments• Describe semagacestat’s mechanism of
action• Explain semagacestat’s role in therapy
![Page 12: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/12.jpg)
Semagacestat’s Mechanism of Acation
Schematic depiction of the process of amyloid-beta (Aβ) protein plaque formation (National Institute on Aging)
https://neurowiki2012.wikispaces.com/Down+Syndrome
Beta and Gamma Secretase
Aβ protein plaques in cortex and hippocampus
APPAmyloid Precursor Protein
![Page 13: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/13.jpg)
Study Objective
• Will semagacestat slow the progression of AD compared to placebo?
![Page 14: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/14.jpg)
Study Design
• Phase 3, multicenter, randomized, parallel, double-blind, placebo-controlled trial
• 1537 patients with mild to moderate AD• 100 mg or 140 mg of semgacestat, or placebo
in a 1:1:1 ratio• Outcome: changes in cognition and
functioning based on assessment scales
Doody RS et al: A Phase 3 Trial of Semagacestat for Treatment of Alzheimer’s Disease. N Engl J Med 2013 369(4)
![Page 15: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/15.jpg)
Methods - Assignment
• Screened 2009 patients, 1537 went randomization• Randomized by site (clinic location) and mild to
moderate AD• Inclusion criteria
– 55 years or older with mild to moderate AD without depression
– Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within the past year with no findings inconsistent with a diagnosis of AD
– Female must be without menstruation 12 consecutive months or have ovaries removed
Doody RS et al.
![Page 16: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/16.jpg)
Methods - Assignment
• Exclusion criteria– Not capable of swallowing whole oral medication– Has serious or unstable illness– Does not have reliable caregiver– Chronic alcohol or drug abuse in past 5 years
• 148 study locations globally
Doody RS et al.
![Page 17: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/17.jpg)
Methods - Protocol
• Study drug, Semagacestat 100 mg or 140 mg, or placebo is dosed once a day for 76 weeks– No more than once daily because of inhibtion of
Notch• Titrate from 60 mg starting dose to assigned
dose to minimize adverse events (AEs)• 20 scheduled clinic visits
Doody RS et al.
![Page 18: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/18.jpg)
Methods - Assessment
• Coprimary outcomes in 76 weeks– Alzheimer’s Disease Assessment Scale for
Cognition (ADAS-cog)– Alzheimer’s Disease Cooperative Study-Activities
of Daily Living scale (ADCS-ADL)• Compare changes of scores from baseline to
endpoint
Doody RS et al.
![Page 19: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/19.jpg)
Methods - Assessment
• Secondary outcomes in 76 weeks– Clinical Dementia Rating –Sum of Boxes (CDR-SB)– Mini-mental State Examination (MMSE)– Neuropsychiatric Inventory (NPI)– Resource Utilization Dementia (RUD-Lite)….
• Subset of patients– Cerebral Spinal Fluid levels (CSF) of Aβ– CSF for tau – Imaging studies
Doody RS et al.
![Page 20: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/20.jpg)
Assesse
ment
Scales
Doody RS et al.
![Page 21: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/21.jpg)
Statistical Analysis
• Interim safety analysis after 50% patients completed 12 months or dropped out– Treatment worse than control (P < 0.05) – Conduct futility analysis, recommend to stop trial
• Mixed model repeated-measures analysis to compare model-adjusted least-squares means at 76 weeks
• All analysis Intent-to-treat (ITT)
Doody RS et al.
![Page 22: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/22.jpg)
Statistical Analysis
• Baseline Characteristics– Categorical variables: Fisher’s Exact or Chi-square
test– Continuous variables: Analysis of Variance (ANOVA)
• Safety analysis based on ITT– Summary listing of adverse events– Fisher’s exact test used for pairwise comparisons
Doody RS et al.
![Page 23: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/23.jpg)
Results – Baseline Characteristics
Doody RS et al.
![Page 24: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/24.jpg)
Results - Mean Change From Baseline
Coprimary
2ndary
Cognition score Daily Living Score
Doody RS et al.
![Page 25: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/25.jpg)
Results – Safety and Adverse Events
• Lost weight in drug group, placebo gained weight (P < 0.001)-1.5 +/- 4.4 kg in 100mg Semagacestat-1.6 +/- 4.7 kg in 140 mg Semagacestat0.4 +/- 3.9 kg in placebo
• Small increase from basline in QT interval for the treatment groups vs placebo (p < 0.001)
• AEs more common with semagacestat groupsMore cancers, skin and subcutaneous tissue disorders (P < 0.001)
Doody RS et al.
![Page 26: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/26.jpg)
Results – Safety and Adverse Events
• Indirect evidence of Fancioni’s syndrome• Hepatocellulary injury, increase in cholesterol
levels, decrease in direct bilirubin, reduction in IgG• Rate of serious AEs higher in treatment group
(P < 0.001)– 24% in 100 mg semagacestat group– 25% in 140 mg semagacestat group– 14% in placebo
• More deaths (9, 14, 6), P = 0.25
Doody RS et al.
![Page 27: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/27.jpg)
Learning Objectives
• Describe Alzheimer’s Disease (AD) and recognize the risk factors
• Describe the pathophysiology of AD• Recall the currently approved drug treatments• Describe semagacestat’s mechanism of action• Explain semagacestat’s role in therapy
![Page 28: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/28.jpg)
Authors’ Conclusion on Semagacestat
• No benefit for treatment of mild-to-moderate AD• Associated with dose related clinical worsening• Study stopped after futility analysis• More adverse events and serious adverse events
Doody RS et al.
![Page 29: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/29.jpg)
Theories on Clinical worsening
• Notch receptors impacted, is semagacestat more selective for Notch that APP?
• Lack of significant reduction in Aβ in CSF?• Other inhibitory substrates?
Doody RS et al.
![Page 30: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/30.jpg)
Application
• No current trials with semagacestat• 40 open trials for AD that are recruiting http://www.clinicaltrials.gov/ct2/results?term=alzheimer%27s+disease&recr=Open&no_unk=Y
• Disease treatment pipeline– Amyloid Beta (Aβ), plaques– Tau protein, neurofibrillary tangles– Improving synaptic transmission– Oxidative stress and inflammatory pathways– Prevent AD– Looking upstream, Aβ plaques can be detected 20 years
before symptomshttp://www.pmlive.com/pharma_news/alzheimers_disease_pipeline_takes_multiple_hits_493398
---- semagacestat target
![Page 31: Semagacestat for Alzheimer's Disease](https://reader031.vdocuments.us/reader031/viewer/2022013003/558ceba4d8b42ac5498b4778/html5/thumbnails/31.jpg)
Questions
http://www.alz.org/braintour/plaques_tangles.asp